Duchenne muscular dystrophy (DMD) is a devastating, inherited muscle-wasting disorder caused by mutations in the DMD gene, leading to an absence of functional dystrophin protein. While current standards of care, such as corticosteroids and supportive therapies, have extended patient lifespans and improved quality of life, they remain largely palliative and do not address the root genetic cause. Among emerging therapies, antisense oligonucleotide (ASO) drugs offer a targeted approach to restore dystrophin production by “skipping” faulty exons during RNA splicing, as was reported by MDPI.com.
Brogidirsen: A Novel Dual-Targeting Approach
Brogidirsen (NS-089/NCNP-02) represents an innovative advance in ASO therapy, specifically targeting exon 44 of the DMD gene. Exon 44 skipping has therapeutic potential for approximately 6–7% of DMD patients, especially those with deletions in this mutational hotspot. Brogidirsen’s unique design links two PMO sequences targeting distinct sites within exon 44, aiming to maximize exon-skipping efficiency and dystrophin restoration without the need for peptide or antibody conjugates.
Clinical Results and Comparison with Peers
Preclinical studies and early clinical trials have shown that brogidirsen can achieve dystrophin expression levels of up to 24% of normal—a figure surpassing the restoration rates of currently approved exon-skipping therapies. In a Phase I/II clinical trial, brogidirsen was well tolerated at doses up to 80 mg/kg/week, with no dose-limiting toxicities or serious adverse events. Muscle biopsies after 24 weeks showed dose-dependent increases in dystrophin, and higher-dose cohorts experienced stabilization or slight improvement in motor function—an encouraging sign in a typically progressive disease.
By contrast, other exon 44-targeting therapies in development, such as AOC1044 (Avidity Biosciences) and ENTR-601-44 (Entrada Therapeutics), employ conjugation to antibodies or cell-penetrating peptides to enhance tissue uptake. These approaches have also demonstrated promising dystrophin restoration in preclinical and early human studies, particularly in cardiac muscle, which is crucial since cardiomyopathy is a leading cause of mortality in DMD.
Challenges and Future Directions
Despite these advances, exon-skipping ASO therapies still face several hurdles. Only a subset of DMD patients can benefit from each exon-specific therapy, and the need for personalized approval and manufacturing processes limits scalability. Off-target effects, immune reactions, and limited delivery to cardiac muscle remain concerns. Additionally, functional outcomes do not always align with increased dystrophin expression, underscoring the need for long-term, robust clinical data.
Nevertheless, brogidirsen’s dual-targeting strategy offers a new paradigm in ASO therapy, potentially enhancing efficacy without added complexity or cost. As larger and longer-term trials progress, brogidirsen could become a key therapy for patients with exon 44 amenable mutations, and its design principles may inspire future RNA-based treatments for DMD and other genetic diseases.
Conclusion
Brogidirsen exemplifies the momentum in RNA-based therapies for DMD, showing that higher dystrophin restoration and a favorable safety profile are achievable. Its novel design and promising results position it at the forefront of next-generation ASO treatments, bringing new hope to patients and families affected by DMD.
